Search

Garrett Robinson

from Baton Rouge, LA
Age ~54
Get Report
Also known as:
Jerrett T Robinson, Jarrett Robinson, Garrett Robison
Related to:
Desiree Robinson, 30Mildred S Smith, 90Desiree G RobinsonDeborah Lynn Robinson, 54Woodrow Robinson, 83Shanell RobinsonMary RobinsonJerrett T Robinson, 54Marva R RobinsonMary N Robinson, 78
Connected to:
Addie M Robinson, 85Adero O Robinson, 52Adjai N Robinson, 91Adreannia Robinson, 43Adriana S Robinson, 56Adrieene L Robinson, 39Afisha S Robinson, 39Ahmed L Robinson, 52Aizan Robinson, 36Ajhia R Robinson, 34

Garrett Robinson Phones & Addresses

  • Baton Rouge, LA
  • Round Rock, TX
  • Pflugerville, TX
  • Austin, TX
  • 7765 Bringhurst Ave, Baton Rouge, LA 70812

Emails

w***[email protected]

Professional Records

Lawyers & Attorneys

Garrett Robinson Photo 1

Garrett Robinson - Lawyer

View page
ISLN:
1001221470
Admitted:
2022

Business Records

Name / Title
Company / Classification
Phones & Addresses
Garrett Robinson
Organizer
TOTAL SYSTEMS TREATMENT ASSOCIATES (T.S.T.A.) LLC

Publications

Us Patents

Cell-Targeting Molecules Comprising De-Immunized, Shiga Toxin A Subunit Effectors And Cd8+ T-Cell Epitopes

View page
US Patent:
20220354938, Nov 10, 2022
Filed:
Jun 29, 2022
Appl. No.:
17/852669
Inventors:
- Austin TX, US
Erin WILLERT - Round Rock TX, US
Sangeetha RAJAGOPALAN - Round Rock TX, US
Garrett Lee ROBINSON - Austin TX, US
Brigitte BRIESCHKE - Austin TX, US
Jason KIM - Austin TX, US
International Classification:
A61K 39/00
A61K 47/68
C07K 14/25
Abstract:
The present invention provides cell-targeting molecules which can deliver a CD8+ T-cell epitope cargo to the MHC class I presentation pathway of a target cell. The cell-targeting molecules of the invention can be used to deliver virtually any CD8+ T-cell epitope from an extracellular space to the MHC class I pathway of a target cell, which may be a malignant cell and/or non-immune cell. The target cell can then display on a cell-surface the delivered CD8+ T-cell epitope complexed with MHC I molecule. The cell-targeting molecules of the invention have uses which include the targeted labeling and/or killing of specific cell-types within a mixture of cell-types, including within a chordate, as well as the stimulation of beneficial immune responses. The cell-targeting molecules of the invention have uses, e.g., in the treatment of a variety of diseases, disorders, and conditions, including cancers, tumors, growth abnormalities, immune disorders, and microbial infections.

De-Immunized, Shiga Toxin A Subunit Scaffolds And Cell-Targeting Molecules Comprising The Same

View page
US Patent:
20220281926, Sep 8, 2022
Filed:
May 17, 2022
Appl. No.:
17/746106
Inventors:
- Austin TX, US
Erin WILLERT - Round Rock TX, US
Garrett Lee ROBINSON - Austin TX, US
Sangeetha RAJAGOPALAN - Round Rock TX, US
Brigitte BRIESCHKE - Austin TX, US
International Classification:
C07K 14/25
C07K 19/00
Abstract:
The present invention relates to Shiga toxin A Subunit derived polypeptides and cell-targeting molecules comprising amino acid substitutions which equip the polypeptides with 1) de-immunization; 2) reduced, protease-cleavage sensitivity; and/or 3) a heterologous epitope cargo(s) while retaining Shiga toxin function(s), such as, e.g., potent cytotoxicity. Certain polypeptides of the invention exhibit reduced immunogenic potential in mammals and/or are capable of delivering an epitope to an MHC class molecule of a cell in which the polypeptide is present. Certain molecules comprising a polypeptide of the invention are well-tolerated by mammals while retaining one or more of the features mentioned above. The Shiga toxin polypeptides of the invention have uses as components of cell-targeting molecules for selectively killing specific cells; for selectively delivering cargos to specific cells, and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers, immune disorders, and microbial infections.

De-Immunized Shiga Toxin A Subunit Effector Polypeptides For Applications In Mammals

View page
US Patent:
20220275030, Sep 1, 2022
Filed:
Jun 11, 2021
Appl. No.:
17/345576
Inventors:
- Austin TX, US
Erin Willert - Round Rock TX, US
Garrett Lee Robinson - Austin TX, US
Sangeetha Rajagopalan - Round Rock TX, US
Brigitte Brieschke - Austin TX, US
International Classification:
C07K 14/25
C07K 14/245
C12N 9/10
C12N 9/24
C12N 15/62
C07K 16/00
C07K 16/08
C07K 16/10
C07K 16/28
C07K 16/32
Abstract:
The present invention relates to Shiga toxin effector polypeptides with reduced antigenic and/or immunogenic potential. Immunogenicity can be a limitation for the repeated administration to mammals of proteins and polypeptides derived from Shiga toxins. The Shiga toxin effector polypeptides of the present invention have uses as components of therapeutics, diagnostics, and immunization materials. The cytotoxic proteins of the present invention have uses for selective killing of specific cell types and as therapeutics for the treatment of a variety of diseases, including cancers, immune disorders, and microbial infections. The proteins of the present invention also have uses for detecting specific cell types, collecting diagnostic information, and monitoring the treatment of a variety of diseases, such as, e.g., cancers, immune disorders, and microbial infections.

Cell-Targeting Molecules Comprising De-Immunized, Shiga Toxin A Subunit Effectors And Cd8+ T-Cell Epitopes

View page
US Patent:
20210268085, Sep 2, 2021
Filed:
Apr 12, 2021
Appl. No.:
17/228579
Inventors:
- Austin TX, US
Erin WILLERT - Round Rock TX, US
Sangeetha RAJAGOPALAN - Round Rock TX, US
Garrett Lee ROBINSON - Austin TX, US
Brigitte BRIESCHKE - Austin TX, US
Jason KIM - Austin TX, US
Assignee:
Molecular Templates, Inc. - Austin TX
International Classification:
A61K 39/00
A61K 47/68
C07K 14/25
Abstract:
The present invention provides cell-targeting molecules which can deliver a CD8+ T-cell epitope cargo to the MHC class I presentation pathway of a target cell. The cell-targeting molecules of the invention can be used to deliver virtually any CD8+ T-cell epitope from an extracellular space to the MHC class I pathway of a target cell, which may be a malignant cell and/or non-immune cell. The target cell can then display on a cell-surface the delivered CD8+ T-cell epitope complexed with MHC I molecule. The cell-targeting molecules of the invention have uses which include the targeted labeling and/or killing of specific cell-types within a mixture of cell-types, including within a chordate, as well as the stimulation of beneficial immune responses. The cell-targeting molecules of the invention have uses, e.g., in the treatment of a variety of diseases, disorders, and conditions, including cancers, tumors, growth abnormalities, immune disorders, and microbial infections.

De-Immunized, Shiga Toxin A Subunit Scaffolds And Cell-Targeting Molecules Comprising The Same

View page
US Patent:
20210253649, Aug 19, 2021
Filed:
Apr 19, 2021
Appl. No.:
17/233911
Inventors:
- Austin TX, US
Erin Willert - Round Rock TX, US
Garrett Lee Robinson - Austin TX, US
Sangeetha Rajagopalan - Round Rock TX, US
Brigitte Brieschke - Austin TX, US
International Classification:
C07K 14/25
C07K 19/00
Abstract:
The present invention relates to Shiga toxin A Subunit derived polypeptides and cell-targeting molecules comprising amino acid substitutions which equip the polypeptides with 1) de-immunization; 2) reduced, protease-cleavage sensitivity; and/or 3) a heterologous epitope cargo(s) while retaining Shiga toxin function(s), such as, e.g., potent cytotoxicity. Certain polypeptides of the invention exhibit reduced immunogenic potential in mammals and/or are capable of delivering an epitope to an MHC class molecule of a cell in which the polypeptide is present. Certain molecules comprising a polypeptide of the invention are well-tolerated by mammals while retaining one or more of the features mentioned above. The Shiga toxin polypeptides of the invention have uses as components of cell-targeting molecules for selectively killing specific cells; for selectively delivering cargos to specific cells, and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers, immune disorders, and microbial infections.

Cell-Targeting Molecules Comprising De-Immunized, Shiga Toxin A Subunit Effectors And Cd8+ T-Cell Epitopes

View page
US Patent:
20200024312, Jan 23, 2020
Filed:
Jan 24, 2018
Appl. No.:
16/480591
Inventors:
- Austin TX, US
Erin WILLERT - Round Rock TX, US
Garrett Lee ROBINSON - Austin TX, US
Brigitte BRIESCHKE - Austin TX, US
Jason KIM - Austin TX, US
Assignee:
MOLECULAR TEMPLATES, INC. - Austin TX
International Classification:
C07K 14/25
A61K 47/68
Abstract:
The present invention provides cell-targeting molecules which can deliver a CD8+ T-cell epitope cargo to the MHC class I presentation pathway of a target cell. The cell-targeting molecules of the invention can be used to deliver virtually any CD8+ T-cell epitope from an extracellular space to the MHC class I pathway of a target cell, which may be a malignant cell and/or non-immune cell. The target cell can then display on a cell-surface the delivered CD8+ T-cell epitope complexed with MHC I molecule. The cell-targeting molecules of the invention have uses which include the targeted labeling and/or killing of specific cell-types within a mixture of cell-types, including within a chordate, as well as the stimulation of beneficial immune responses. The cell-targeting molecules of the invention have uses, e.g., in the treatment of a variety of diseases, disorders, and conditions, including cancers, tumors, growth abnormalities, immune disorders, and microbial infections.

De-Immunized, Shiga Toxin A Subunit Scaffolds And Cell-Targeting Molecules Comprising The Same

View page
US Patent:
20180258143, Sep 13, 2018
Filed:
May 27, 2016
Appl. No.:
15/577827
Inventors:
- Austin TX, US
Erin WILLERT - Round Rock TX, US
Garrett Lee ROBINSON - Austin TX, US
Sangeetha RAJAGOPALAN - Round Rock TX, US
Brigitte BRIESCHKE - Austin TX, US
Assignee:
Molecular Templates, Inc. - Austin TX
International Classification:
C07K 14/25
C07K 19/00
Abstract:
The present invention relates to Shiga toxin A Subunit derived polypeptides and cell-targeting molecules comprising amino acid substitutions which equip the polypeptides with 1) de-immunization; 2) reduced, protease-cleavage sensitivity; and/or 3) a heterologous epitope cargo(s) while retaining Shiga toxin function(s), such as, e.g., potent cytotoxicity. Certain polypeptides of the invention exhibit reduced immunogenic potential in mammals and/or are capable of delivering an epitope to an MHC class molecule of a cell in which the polypeptide is present. Certain molecules comprising a polypeptide of the invention are well-tolerated by mammals while retaining one or more of the features mentioned above. The Shiga toxin polypeptides of the invention have uses as components of cell-targeting molecules for selectively killing specific cells; for selectively delivering cargos to specific cells, and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers, immune disorders, and microbial infections.

De-Immunized Shiga Toxin A Subunit Effector Polypeptides For Applications In Mammals

View page
US Patent:
20160340394, Nov 24, 2016
Filed:
Jan 26, 2015
Appl. No.:
15/114487
Inventors:
- Georgetown TX, US
Erin Willert - Round Rock TX, US
Garrett Lee Robinson - Austin TX, US
Sangeetha Rajagopalan - Round Rock TX, US
Brigitte Brieschke - Austin TX, US
Assignee:
Molecular Templates, Inc. - Georgetown TX
International Classification:
C07K 14/25
C07K 16/28
C07K 16/32
C12N 9/24
C07K 16/00
C07K 16/10
C12N 9/10
C07K 14/245
C07K 16/08
Abstract:
The present invention relates to Shiga toxin effector polypeptides with reduced antigenic and/or immunogenic potential. Immunogenicity can be a limitation for the repeated administration to mammals of proteins and polypeptides derived from Shiga toxins. The Shiga toxin effector polypeptides of the present invention have uses as components of therapeutics, diagnostics, and immunization materials. The cytotoxic proteins of the present invention have uses for selective killing of specific cell types and as therapeutics for the treatment of a variety of diseases, including cancers, immune disorders, and microbial infections. The proteins of the present invention also have uses for detecting specific cell types, collecting diagnostic information, and monitoring the treatment of a variety of diseases, such as, e.g., cancers, immune disorders, and microbial infections.
Control profile
Garrett Robinson from Baton Rouge, LA, age ~54 Get Report